Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

CACure

Financiado

Generating mRNA-HNF4a-Lipid nanoparticles for curing pancreatic cancer-associate...

Generating mRNA-HNF4a-Lipid nanoparticles for curing pancreatic cancer-associated cachexia (CAC) in identified patients at risk "Cancer-associated cachexia (CAC) is a multifactorial syndrome causing significant morbidity and mortality in cancer patients and indicates a poor prognosis. Nearly 80% of cancer patients experience CAC, which directly accounts fo... ver más

31/08/2024

WEIZMANN

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 1 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-08-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2

I+D

Cerrada hace 2 años

0% 100%

1 Participantes

WEIZMANN

150.00K€ | Lider

Proyectos interesantes

TRAIN Tumor Regulation Assisted by Immunity and Nanotechnology 157K€ Cerrado

SAF2011-28350 APLICACIONES DE LA RMN Y LA METABOLOMICA AL DESARROLLO DE NU... 230K€ Cerrado

RTC2019-007229-1 PrediApt: Desarrollo de un Sistema Predictivo de Respuesta a... 128K€ Cerrado

MATADOR MAmmary chemoresistant Tumor deAth by Directed cell ORientat... 150K€ Cerrado

OvaCTool Personalized medicine in ovarian cancer: Design and developm... 181K€ Cerrado

SAF2013-48657-R MODULACION DE LA PROGRESION TUMORAL POR ENZIMAS PI3K: APROXI... 484K€ Cerrado

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2023-02-27
Fecha Fin: 2024-08-31

Líder del proyecto

WEIZMANN INSTITUTE OF SCIENCE

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto "Cancer-associated cachexia (CAC) is a multifactorial syndrome causing significant morbidity and mortality in cancer patients and indicates a poor prognosis. Nearly 80% of cancer patients experience CAC, which directly accounts for almost 20% of all cancer deaths, mainly in patients with pancreatic adenocarcinoma (PDAC). Clinically, CAC manifests as weight loss and wasting of skeletal muscle mass. Thus, CAC patients experience reduced physical, emotional, and social well-being, leading to increased use of healthcare resources. The massive phenotypic manifestations point to a significant imbalance in the systemic metabolism of CAC patients. Unlike starvation, CAC cannot be reversed by standard nutritional interventions, and currently, there are no biomarkers for identifying patients at risk for CAC and no effective therapeutic modalities. With our ERC (#818943), we identified changes in liver metabolism during extra hepatic carcinogenesis. We now demonstrate that these metabolic changes occur early, precede CAC, and can be diagnosed by routine liver biochemical profile. We generated a biochemical liver score that can identify PDAC patients at risk for CAC, irrespective of disease stage at diagnosis. Furthermore, we find that these metabolic changes in the liver are mediated by early infiltrating immune cells that lead to HNF4a depletion in hepatocytes independent of liver metastasis. Importantly, we find that re-expressing HNF4a with Adeno Associated Virus (AAV8) preserves liver metabolism in PDAC mouse models and alleviates CAC. We hence hypothesize that generating liver-specific mRNA of HNF4a will be highly therapeutically beneficial for PDAC patients identified by our liver score to be at risk for CAC. In this PoC we will generate and test the efficiency of novel HNF4a-mRNA-LNPs in preventing or alleviating CAC in PDAC mouse models. When successful, our optimized construct will undoubtedly serve identified PDAC and other cancer patients at risk for CAC. "

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores